The UK’s National Institute for Health and Care Excellence (NICE) has recommended Elfabrio (pegunigalsidase alfa) as an option for treating Fabry disease (or alpha-galactosidase deficiency). The drug is recommended for use on the NHS under the terms of a confidential commercial agreement. Pegunigalsidase alfa is a novel enzyme replacement therapy (ERT) administered via intravenous infusion […]
